{{Infobox company
| name = Regeneron Pharmaceuticals, Inc.<br>再生元制药
| logo = Regeneron logo.svg
| logo_size = 250px
| image = New Eastview office bldg jeh.jpg
| image_caption = 总部大楼
| type = [[上市公司|上市公司]]
| traded_as = {{Unbulleted list|{{NASDAQ|REGN}}|[[NASDAQ-100|NASDAQ-100]]成分股|[[S&P_500|S&P 500]]成分股}}
| foundation = 1988
| location = {{USA}}纽约州[[欢喜山_(纽约州)|欢喜山]]
| area_served = 全球
| key_people = Leonard Schleifer（CEO）
| industry = [[制药|制药]]、[[生物科技|生物科技]]
| revenue = {{increase}} $58亿
| operating_income = 
| assets =
| equity = 
| num_employees = 6,200<ref>{{Cite web|url=http://fortune.com/fortune500/regeneron-pharmaceuticals/|title=Regeneron Pharmaceuticals|website=Fortune|access-date=2018-12-31}}</ref>
| num_employees_year = 2017
| net_income = {{increase}} $14亿
| homepage = {{url|www.regeneron.com}}
}}

'''再生元製藥'''（Regeneron Pharmaceuticals, Inc.） 是一家美国制药公司。

==历史==
成立于1988年<ref name=herper2013>{{cite news | url=https://www.forbes.com/sites/matthewherper/2013/08/14/how-two-guys-from-queens-are-changing-drug-discovery/ | deadurl=no | title=How Two Guys From Queens Are Changing Drug Discovery | date=August 14, 2013 | author=Herper, Matthew | work=[[Forbes|Forbes]] | location=United States | accessdate=March 22, 2014 | archivedate=March 16, 2014 | archiveurl=https://web.archive.org/web/20140316003731/http://www.forbes.com/sites/matthewherper/2013/08/14/how-two-guys-from-queens-are-changing-drug-discovery/ }}{{open access}}</ref>。最初主要研究[[神经营养因子|神经营养因子]]及其再生能力，后来也开始研究[[细胞因子|细胞因子]]等其他领域。

==产品==
产品包括眼科药物[[阿柏西普|阿柏西普]]<ref name=herper2013 /><ref name=apnyt2011>{{cite news | url=https://www.nytimes.com/2011/11/19/business/regulators-approve-a-drug-for-an-eye-condition.html | title=Regulators Approve a Drug for an Eye Condition | work=[[The_New_York_Times|The New York Times]] | agency=Associated Press | date=November 18, 2011 }}{{registration required}}</ref>、预防痛风急性发作的[[rilonacept|rilonacept]]。它和[[赛诺菲|赛诺菲]]合作开发有降脂药[[alirocumab|alirocumab]]<ref>{{Cite web |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm |title=Archived copy |access-date=2015-07-29 |archive-url=https://web.archive.org/web/20150727112659/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm |archive-date=2015-07-27 |dead-url=yes |df= }}</ref>、治疗哮喘的[[dupilumab|dupilumab]]<ref>{{cite web|url=http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biologic-therapy-for-adults-with-moderate-to-severe-atopic-dermatitis-300430441.html|title=Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis|first=Regeneron Pharmaceuticals,|last=Inc.|website=www.prnewswire.com}}</ref>、抗炎药[[sarilumab|sarilumab]]<ref>{{cite web|url=http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=1027419|title=Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN)|website=newsroom.regeneron.com}}</ref>以及治疗晚期皮肤鳞状细胞癌的[[cemiplimab|cemiplimab]]<ref>{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622044.htm|title=FDA approves first treatment for advanced form of the second most common skin cancer (NASDAQ:REGN)|website=fda.gov/NewsEvents}}</ref>。

==参考文献==
{{Reflist}}

==外部连接==
{{commonscat}}
* {{official website|1=http://www.regeneron.com}}
{{Finance links
| name = Regeneron 
| symbol = REGN
| sec_cik = REGN
| yahoo = REGN
| google = REGN
}}
*[https://www.nytimes.com/2011/11/21/business/eylea-a-vision-drug-wins-long-sought-approval.html Success Long in Coming for Eylea, a Vision Treatment]

{{NASDAQ-100}}

[[Category:美国制药公司|Category:美国制药公司]]
[[Category:1988年成立的公司|Category:1988年成立的公司]]